Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hoerter Steven L. (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]						GIO (Ch	5. Relationship of Reporting Per- (Check all applicable) Director X Officer (give title below)			10% Ow Other (s below)	ner
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS 88 SIDNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/16/2018							Chi	ief Comn	iercia	l Officer	
(Street)	IDGE M	A	02139		I. If Ame	endment, I	Date o	f Original Filed (Month/Day/Year)			Line	X Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	tate)	(Zip)									Persor	1			
1. Title of Security (Instr. 3) 2. Transac Date				Transact	2A. Deemed Execution Date,		3. Transactio	Transaction Disposed Of (D) (Instr. 3, 2) Code (Instr. 5)		ed (A) or	5. Amour Securitie Beneficia Owned F	nt of 6 s F	Form (D) o	orm: Direct D) or Indirect () (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V			Amoun	(A) or (D)	Price	Reported Transact (Instr. 3 a	tion(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Executi (Month/Day/Year) if any	3A. Deemed Execution Dat if any (Month/Day/Ye	Cod	saction e (Instr.	of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock option (right to buy)	\$77.7	02/16/2018		A		33,000		(1)	02/15/2028	Common stock	33,000	\$0.00	33,00	0	D	
Restricted stock units	(2)	02/16/2018		A		8,250		(3)	(3)	Common stock	8,250	\$0.00	8,250)	D	

Explanation of Responses:

- 1. This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 3. The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

/s/ William Cook, as Attorneyin-fact for Steven Hoerter

02/20/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.